Enhertu Significantly Delayed Breast Cancer Progression in Trial, AstraZeneca Says
15 August 2022 - 8:42AM
Dow Jones News
By Kyle Morris
AstraZeneca PLC said Monday that its Enhertu drug significantly
delayed metastatic breast cancer progression in a Phase 3 trial,
reinforcing the results of a prior trial.
The Anglo-Swedish pharma giant said results from the
Destiny-Breast02 Phase 3 trial of Enhertu--trastuzumab
deruxtecan--showed the trial met the primary endpoint,
demonstrating a significant and clinically meaningful improvement
in progression-free survival in patients.
Enhertu is being jointly developed and commercialized by
AstraZeneca and Daiichi Sankyo Ltd.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
August 15, 2022 02:27 ET (06:27 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
